1. Home
  2. CDXS vs BKT Comparison

CDXS vs BKT Comparison

Compare CDXS & BKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDXS
  • BKT
  • Stock Information
  • Founded
  • CDXS 2002
  • BKT 1988
  • Country
  • CDXS United States
  • BKT United States
  • Employees
  • CDXS N/A
  • BKT N/A
  • Industry
  • CDXS Major Chemicals
  • BKT Investment Bankers/Brokers/Service
  • Sector
  • CDXS Industrials
  • BKT Finance
  • Exchange
  • CDXS Nasdaq
  • BKT Nasdaq
  • Market Cap
  • CDXS 216.6M
  • BKT 245.7M
  • IPO Year
  • CDXS 2010
  • BKT N/A
  • Fundamental
  • Price
  • CDXS $2.09
  • BKT $11.20
  • Analyst Decision
  • CDXS Buy
  • BKT
  • Analyst Count
  • CDXS 2
  • BKT 0
  • Target Price
  • CDXS $11.00
  • BKT N/A
  • AVG Volume (30 Days)
  • CDXS 656.9K
  • BKT 67.9K
  • Earning Date
  • CDXS 11-06-2025
  • BKT 01-01-0001
  • Dividend Yield
  • CDXS N/A
  • BKT 8.97%
  • EPS Growth
  • CDXS N/A
  • BKT N/A
  • EPS
  • CDXS N/A
  • BKT N/A
  • Revenue
  • CDXS $57,164,000.00
  • BKT N/A
  • Revenue This Year
  • CDXS $12.88
  • BKT N/A
  • Revenue Next Year
  • CDXS $21.64
  • BKT N/A
  • P/E Ratio
  • CDXS N/A
  • BKT N/A
  • Revenue Growth
  • CDXS N/A
  • BKT N/A
  • 52 Week Low
  • CDXS $1.90
  • BKT $10.55
  • 52 Week High
  • CDXS $6.08
  • BKT $12.92
  • Technical
  • Relative Strength Index (RSI)
  • CDXS 31.30
  • BKT 47.54
  • Support Level
  • CDXS $2.52
  • BKT $11.10
  • Resistance Level
  • CDXS $2.80
  • BKT $11.19
  • Average True Range (ATR)
  • CDXS 0.14
  • BKT 0.08
  • MACD
  • CDXS -0.06
  • BKT 0.01
  • Stochastic Oscillator
  • CDXS 1.54
  • BKT 61.11

About CDXS Codexis Inc.

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

About BKT BlackRock Income Trust Inc. (The)

Blackrock Income Trust Inc is a diversified investment fund with an investment objective to manage a portfolio of high-quality securities to achieve both preservations of capital and high monthly income. The trust seeks to achieve its investment objective by investing at least 65 percent of its assets in mortgage-backed securities. The Fund invests at least 80 percent of its assets in securities that are (i) issued or guaranteed by the U.S. government or one of its agencies or instrumentalities or (ii) rated at the time of investment either AAA by S&P Global Ratings (S&P) or Aaa by Moody's Investors Service, Inc (Moody's). The Fund may invest directly in such securities or synthetically through the use of derivatives.

Share on Social Networks: